MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients
— Orally administered MP1032 with very favorable safety and tolerability profile
— Compound equally effective as Remdesivir or Nirmatrelvir/Ritonavir as monotherapy
— Oral administration and suitability for early intervention address high unmet medical need
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory diseases, today announced topline data of its CT05 Phase IIa double-blind placebo-controlled study of small molecule macrophage metabolic modulator MP1032 in COVID-19 patients.